Posted by Michael Wonder on 07 Feb 2024
Rhythm Pharmaceuticals announces positive reimbursement decision in Italy for Imcivree (setmelanotide) for the treatment of obesity and control of hunger in Bardet-Biedl syndrome
7 February 2024 - Rhythm Pharmaceuticals today announced that the Italian Medicine Agency (AIFA) approved reimbursement (Gazzetta Ufficiale) for Imcivree (setmelanotide) for the treatment of obesity and control of hunger associated with Bardet-Biedl syndrome.
AIFA previously approved reimbursement for Imcivree for the treatment of obesity and control of hunger associated with biallelic proopiomelanocortin, proprotein convertase subtilisin/kexin type 1, or biallelic leptin receptor deficiency.
